• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The global obesity epidemic is well established, with increases in obesity prevalence for
most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied
in the past decade, but effective approaches to prevent and treat this disease are limited …